1Grompe M.The pathophysiology and treatment of hereditary tyrosinemia type 1.Semin Liver Dis,2001,21:563-571.
2Croffie JM,Gupta SK,Chong SKF,et al.Tyrosinemia type 1 should be suspected in infants with severe coagulopathy even in the absence of other signs of liver failure.Pediatrics,1999,103:675-678.
3Kvittingen EA.Tyrosinaemia type Ⅰ-an update.J Inher Metab Dis,1991,14:554-562.
6Chakrapani A, Holme E. Disorders of tyrosine metabolism// Fernandes J, Saudubray JM, Berghe G, et al. Inborn Metabolic Diseases. 4th ed. Germany: Springer, 2006: 233-243.
7Rashed MS, Ahaidib LY, A1-Dirbashi OY, et al. Tandem mass spectrometric assay of succinylacetone in urine for the diagnosis of hepatorenal tyrosinemia. Analytical Biochemistry, 2005, 339 : 310-317.
8Allard P, Grenier A, Korson MS, et al. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin Biochem, 2004,37 : 1010-1015.
9Masurel-Paulet A, Poggi-Bach J, Rolland MO, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French.patients. J Inherit Metab Dis,2008, 31:81-87.
10Ohura T, Kobayashi K, Tazawa Y, et al. Clinical pictures of 75 patients with neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD). J Inherit Metal) Dis, 2007, 30:139-144.
